Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease
Tiziana Life Sciences dosed the last patient in its Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early/mild Alzheimer's disease, completing enrollment. The trial evaluates foralumab as monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab (Leqembi) or donanemab, with key endpoints including TSPO-PET neuroinflammation measures, cognition, and amyloid/tau biomarkers.
Key figures
- Drug Name
- intranasal foralumab (fully human anti-CD3 monoclonal antibody)
- Phase Of Trial
- Phase 2
- Topline data expected
- Q1 2027
- Expanded access patients dosed
- 14
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.